Table 7.
Changes in FGF21, some laboratory data, and imaging before and at the end of treatment with SOF/SIM (12 weeks) in CHC patients (n=75)
| Variables | Before treatment | End of treatment | P-values |
|---|---|---|---|
| Hb (g/dL) | 13.6±1.3 | 12.7±1.5 | 0.001* |
| Platelets (×109/L) | 196.09±59.1 | 194.6±37.06 | 0.7 |
| ALT (IU/L) | 49.8±21.4 | 41.6±14.4 | 0.001* |
| AST (IU/L) | 50.2±25.2 | 40.2±17.3 | 0.001* |
| FGF21 (ng/mL) | 123.7±52.5 | 60.5±32.7 | 0.001* |
| FIB-4 | 1.9±1.08 | 1.7±1.1 | 0.03* |
| Fibroscan | 13.6±10.4 | 12.6±8.8 | 0.001* |
Notes:
*
Significance. Data presented as mean ± SD.
Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; FGF21, fibroblast growth factor 21; FIB-4, Fibrosis-4 Index for Liver Fibrosis; Hb, hemoglobin.